

Recent and Upcoming Changes and Challenges in the EU

Manfred Maeder PhD Head Device Development & Commercialization (BTDM) Novartis



This presentation is based on publicly available information;

These slides are intended for educational purposes only and for the personal use of the audience. These slides are not intended for wider distribution outside the intended purpose without presenter approval;

The content of this slide deck is accurate to the best of the presenter's knowledge at the time of production.

The views and opinions expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of Novartis or any of its officers.





Background

US expectation

Upcoming MDR requirements

Why do more and more drugs need medical devices?



Medical innovation continues to move forward fast

Empowered patients & consumers are demanding new ways to augment benefit of products leading to more drug products being combined with a device

Advances in digital technology are supporting trend towards measuring & improving costeffectiveness

Non-traditional healthcare companies like Google, Apple, IBM... are entering healthcare field in search of opportunities

The term Combination Product results from three designations




 Including "any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect."

Source: FDA, 21CFR3.2 (e)



...drug products combined with a device (fixed combination or co-package)



Heterogeneous global Combination Product regulatory landscape

	Formal Definition in Regulation	Formal Status Determination Mechanism	Evaluation Process	Manu- facturing Controls	Labelling	Postmarket Reporting
USA	\checkmark	\checkmark		PMOA DE CP	🤹 🗉	РМОА
European Commission	*	\checkmark			۵	РМОА СР
Australia	×	\checkmark	*	PMOA CP	PMOA CP	РМОА СР
🛑 Japan	*	×	РМОА	РМОА	🤹 🔳	РМОА
Canada	\checkmark	\checkmark	РМОА	PMOA DE CP	PMOA CP	РМОА
*) China	\checkmark	\checkmark	РМОА		***	\checkmark
Singapore	\checkmark	\checkmark	РМОА	РМОА	РМОА	РМОА
🛞 India	\checkmark	\checkmark	РМОА	РМОА	3	3
South Korea	\checkmark	\checkmark		PMOA CP	РМОА СР	РМОА СР
Sector Hong Kong	×	×	PMOA CP	РМОА	РМОА	РМОА
* Taiwan	✓ 1	✓ 1	РМОА			РМОА
Thailand	×	\checkmark	РМОА	3	РМОА	РМОА
Malaysia	×	\checkmark	٢.	РМОА СР	3	РМОА
Saudi Arabia	✓	\checkmark	РМОА	РМОА	РМОА СР	РМОА

Legend: Yes: ✓ Regulations or practice applicable to PMOA applied: ②◎ R No: × Cross labelling requirements for co-dependent products: ■ U Source: Asian Harmonization Working Party N.B.: Data from 2015

Parenteral Drug Association

Regulations for all components applied: Undefined – no regulation or guidance established: 2. Guidance in preparation Regulations under development:



Challenges for global development






Expectations on defect notification (recalls)



HFE & HFE related "guidelines"






End of transition Into force Date of application May 26th May 25th May 26th 2017 2020 2025 Products can be made available for 5 Product **placed** on the market according to MDD more years 'making available on the market" 'placing on the market' means the means any supply of a device... first making available of a device, for distribution, consumption or use on other than an investigational device, the Union market in the course on the Union market of a commercial activity



Comparison MDD to MDR



11



Final version of MDR consists of ten chapters - Facts about the MDR

Chapter	Description	Articles
1	Scope and definitions	1 – 4
2	Making available on the market	5 – 24
3	Identification and traceability of devices	25 – 34
4	Notified bodies	35 – 50
5	Classification and conformity assessment	51 – 60
6	Clinical evaluation and clinical investigations	61 – 82
7	PMS, vigilance and market surveillance	83 - 100
8	Cooperation between Member States	101 – 108
9	Confidentiality	109 – 113
10	Final provisions	114 – 123



2

Key issues in the MDR – main chapters (I / IV)

Making available on the market

- General obligations of distributors
- "Person responsible for regulatory compliance
- Marking identification number also on promotional material

3 Identification and traceability of devices

- Multiple Unique Device Identification (UDI) System and respective database
- Registration on manufacturers single registration number (SRN)



Key issues in the MDR – main chapters (II / IV)

Notified bodies

- New application for MDR; MDD notification is not automatically transferred
- Increased notification and monitoring requirements
- Coordination and cooperation of notified bodies

5 Classification and conformity assessment

- Conformity assessment reduced to three procedures
- Application in parallel with more than one notified body is <u>explicitly</u> <u>interdicted</u>



Key issues in the MDR – main chapters (III / IV)

6 Clinical evaluation & clinical investigations


Stricter requirements on clinical evaluation:

- Evaluation of relevant scientific literature AND
- Evaluation of the results of all available clinical investigations AND
- Consideration of available alternative treatment options
- Equivalence to an already marketed device by another manufacturer (in order to avoid a clinical investigation) requires "full access to the technical documentation on an ongoing basis"



Key issues in the MDR – main chapters (IV / IV)

PMS, vigilance and market surveillance





Key issues also identified in the MDR Annex



Requirements to be met by notified bodies

- More strict requirements on audit criteria and assessment of technical documentation
- Strict requirements on handling of changes and modifications

9

- Conformity assessment based on a quality management system and assessment of the technical documentation
- Criteria for documents to be submitted to the notified body (application for QMS assessment)
- At least once every five years an unannounced audit is to be performed







Acknowledgements